Personalis aims to lead the MRD liquid biopsy market with ultra-sensitive sequencing and upcoming Medicare coverage. Read here for more on PSNL stock.

Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an ...

The BMP8A Fibrosis Score (BFS) offers improved accuracy over existing noninvasive scoring systems for identifying advanced liver fibrosis in MASH patients. BFS eliminates grey-zone results, providing ...

London, Ontario: Dr. John McNaught, FRCSC, OB/GYN, MD and his teams at CReATe Fertility and London Women’s Health Care are focused on improving diagnosis of endometriosis at their London, Ontario ...

Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...

SGLT2 inhibitors are a welcome addition to GN care, but the field is still grappling with the gap between molecular ...

Background Bronchoscopic limitations in reaching peripheral pulmonary lesions (PPLs) can compromise biopsy sensitivity, ...

Routine screening is limited to only a few cancer types. New research indicates that routine liquid biopsy testing (multi-cancer early detection testing) could substantially reduce late-stage cancer ...

The MarketWatch News Department was not involved in the creation of this content. Launched in 2019, the Syn-One Test is used by neurologists and other clinicians in all 50 states to aid in the ...

CND Life Sciences announces 50,000 skin biopsy-based Syn-One Tests completed, aiding in synucleinopathy diagnoses. "Neurologists and other clinicians continue to express their earnest appreciation for ...

—Canio Martinelli, MD, Director of Clinical and Translational Research, Sbarro Health Research Organization at Temple University in Philadelphia, discusses this rapidly evolving field. Liquid biopsy ...